Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report

Okita,Yoshiko; Nonaka,Masahiro; Umehara,Toru; Kanemura,Yonehiro; Kodama,Yoshinori; Mano,Masayuki; Nakajima,Shin

doi:10.3892/ol.2015.2940

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report

Authors:
- Yoshiko Okita
- Masahiro Nonaka
- Toru Umehara
- Yonehiro Kanemura
- Yoshinori Kodama
- Masayuki Mano
- Shin Nakajima
View Affiliations

Affiliations: Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan, Department of Central Laboratory and Surgical Pathology, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
Published online on: February 6, 2015 https://doi.org/10.3892/ol.2015.2940
Pages: 1885-1888

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of leptomeningeal dissemination of recurrent glioblastoma is poor, and chemotherapy results in minimal palliative efficacy. Temozolomide (TMZ) is an established therapy for patients with malignant glioma and the standard of care in parenchymal gliomas; however, few reports have been published with regard to its use for the treatment of leptomeningeal dissemination. Only one report has indicated the radiographic response of leptomeningeal dissemination to a TMZ rechallenge, suggesting a potential causative effect. While bevacizumab is an effective therapy for recurrent glioblastoma, its effect on leptomeningeal dissemination of recurrent glioblastoma remains unclear. The present study reports a case of leptomeningeal dissemination of recurrent glioblastoma in which transient neurological and radiological improvement was observed following chemotherapy with TMZ and bevacizumab. However, five months after the diagnosis of leptomeningeal dissemination the patient succumbed to the disease.

View Figures

View References

1	Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lamborn KR, Yung WK, Chang SM, et al; North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 10:162–170. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 17:2572–2578. 1999.PubMed/NCBI
4	Arita N, Taneda M and Hayakawa T: Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien). 126:84–92. 1994. View Article : Google Scholar
5	Awad I, Bay JW and Rogers L: Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery. 19:247–251. 1986. View Article : Google Scholar : PubMed/NCBI
6	Vertosick FT Jr and Selker RG: Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series. Neurosurgery. 27:516–522. 1990. View Article : Google Scholar : PubMed/NCBI
7	Delattre JY, Walker RW and Rosenblum MK: Leptomeningeal gliomatosis with spinal cord or cauda equina compression: a complication of supratentorial gliomas in adults. Acta Neurol Scand. 79:133–139. 1989. View Article : Google Scholar : PubMed/NCBI
8	Nandipati S and Demopoulos A: Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide. J Neurooncol. 105:663–665. 2011. View Article : Google Scholar : PubMed/NCBI
9	Narita Y: Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin Oncol. 43:587–595. 2013. View Article : Google Scholar : PubMed/NCBI
10	Groves MD, DeGroot J, Tremont I, Forman A, Kang S, Pei BL, et al: A pilot study of systemically administered bevacizumab with neoplastic meningitis NM: imaging, clinical, CSF, and biomarker outcomes. Neuro Oncol (OT-02). 13:iii85–iii91. 2011.
11	Fiorentino A, Caivano R, Chiumento C, Cozzolino M and Fusco V: Radiotherapy and bevacizumab for intramedullary and leptomenigeal metastatic glioblastoma: a case report and review of the literature. Int J Neurosci. 122:691–694. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hübner F, Braun V and Richter HP: Case reports of symptomatic metastases in four patients with primary intracranial gliomas. Acta Neurochir (Wien). 143:25–29. 2001. View Article : Google Scholar
13	Onda K, Tanaka R, Takahashi H, Takeda N and Ikuta F: Cerebral glioblastoma with cerebrospinal fluid dissemination: a clinicopathological study of 14 cases examined by complete autopsy. Neurosurgery. 25:533–540. 1989. View Article : Google Scholar : PubMed/NCBI
14	Chamberlain MC: Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery. 52:324–330. 2003. View Article : Google Scholar : PubMed/NCBI
15	Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
16	Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
17	Giantonio BJ, Catalano PJ, Meropol NJ, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
18	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
19	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
20	Vincent A, Lesser G, Brown D, et al: Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer. 16:122–126. 2013. View Article : Google Scholar : PubMed/NCBI
21	De Braganca KC, Janjigian YY, Azzoli CG, et al: Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol. 100:443–447. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ku GY, Krol G and Ilson DH: Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol. 25:e14–e16. 2007. View Article : Google Scholar : PubMed/NCBI
23	Le Rhun E, Taillibert S and Chamberlain MC: Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 4:S265–S288. 2013.PubMed/NCBI
24	Mohan A and Ponnusankar S: Newer therapies for the treatment of metastatic breast cancer: a clinical update. Indian J Pharm Sci. 75:251–261. 2013. View Article : Google Scholar : PubMed/NCBI
25	Foubert F, Matysiak-Budnik T and Touchefeu Y: Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis. 46:105–112. 2014. View Article : Google Scholar
26	Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
27	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
28	Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
29	Chamberlain MC and Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol. 96:259–269. 2010. View Article : Google Scholar
30	Wong ET, Gautam S, Malchow C, Lun M, Pan E and Brem S: Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw. 9:403–407. 2011.PubMed/NCBI